Kelly Peck
Primary Care · Palm Desert, CANPI 1235856071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,422, 6.6 times the $214 reported in 2022. Among primary care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$651
- GSK$649
- AstraZeneca$404
- Novo Nordisk$340
- Boehringer Ingelheim$276
- AbbVie$201
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,10099%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,150 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $10,761 |
| Gabapentin | 73 | $1,344 |
| Levothyroxine Sodium | 105 | $1,264 |
| Potassium Chloride | 30 | $851 |
| Buspirone Hcl | 36 | $708 |
| Atorvastatin Calcium | 53 | $527 |
| Losartan Potassium | 70 | $463 |
| Estradiol | 16 | $349 |
| Celecoxib | 17 | $333 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $289 |
| Duloxetine Hcl | 12 | $267 |
| Trazodone Hcl | 56 | $253 |
| Ciprofloxacin Hcl | 29 | $219 |
| Pantoprazole Sodium | 19 | $211 |
| Metformin Hcl | 24 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $404 | $10,76111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 706 primary care providers in California.
Other primary care in Palm Desert
- Joann BallPalm Desert$8K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.